| Ytd | -82.31% | |
| 1y | -83.84% |
| Open | 0.94 | Prev Close | 0.95 | Low | 0.92 | High | 0.97 | Mkt Cap | 55.28M |
| Vol | 699.27K | Avg Vol | 1.18M | EPS | -0.37 | P/E | N/A | Forward P/E | -7.80 |
| Beta | 1.43 | Short Ratio | 6.19 | Inst. Own | 62.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 1.41 | 200-d Avg | 2.59 | 1yr Est | 10.00 |
ALDX News
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesd
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular s
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) wi
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to
Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye dru
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Di
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintain
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FD
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnolog
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnolog
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Deve
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnol
Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feed
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnol
New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a national
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors o
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potent
LOS ANGELES--(BUSINESS WIRE)---- $ALDX--ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics
New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights
NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Faruqi & Faruqi, LLP, a leading national securities law f
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareho
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remin
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, r
Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy
Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested i
HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) fr
Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Ge
US stocks rose, with Dow Jones up 0.39% & NASDAQ up 0.59%. Energy shares jumped 1.7%, while indu
US stocks started higher this morning, with NASDAQ up over 100 points. Energy shares rose by 1.3%, w
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a
FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to ne
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintain
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agenc
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Admin
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) wi